Many scientists and medical experts have warned that vaccinating children against COVID-19 is both unnecessary and risky in the extreme. The video above features comments by Peter Doshi, Ph.D., made during a June 10, 2021, public hearing by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee.
Doshi is an associate professor at the University of Maryland School of Pharmacy and the senior editor of The BMJ. He has previously pointed out that while Pfizer claims its vaccine is 95% effective, this is the relative risk reduction. The absolute risk reduction — which is far more relevant for public health measures — is actually less than 1%.1 As such, the COVID-19 vaccine is of dubious benefit, to say the least.
If you choose to watch the video above I must warn you to stop after Doshi finishes and not view the presentation by Dr. Jacqueline Miller. She’s a paid shill pediatrician and the head of development for infectious diseases at Moderna. The reason I advise this caution is because if you understand reality, you will be shocked at how easily a physician can sell out and sacrifice even her own children in the delusional belief that Moderna’s shot provides any benefit to children.
Meanwhile, largely because of irresponsible beliefs and comments like Miller’s, harms are rapidly mounting, which skews the risk-benefit ratio even further. Considering the potential for harm, children should not get the COVID-19 vaccine, Doshi says, citing trial evidence from Pfizer — the very same evidence used to support its emergency use authorization application for 12- to 15-year-olds. In this trial, harms clearly outweighed the benefits.
While benefits were rare and short-lived, side effects were common and long-term effects are completely unknown. In the 12-to-15 age group, 75.5% experienced headache, along with a long list of other transient side effects. However, more serious systemic adverse events also occurred in 2.4% of the trial subjects receiving the actual mRNA shot.
Now, Pfizer boasted a 100% efficacy rate in this age group. This, Doshi explains, was based on 16 cases occurring in the placebo group, while no cases were recorded in the vaccine group. However, since there were about 1,000 placebo recipients, fewer than 2% of the placebo group actually tested positive for COVID-19.
“Put another way, 2% of the fully vaccinated avoided COVID,” Doshi says, adding “98% of the vaccinated wouldn’t have gotten COVID anyway … So, the benefit is small.”
One of the reasons for why children reap so little benefit from this jab is because a significant portion of American children are already immune and aren’t at risk of infection to begin with. Doshi cites Centers for Disease Control and Prevention data showing an estimated 23% of children under the age of 4 and 42% of those age 5 through 17 have already had a SARS-CoV-2 infection and now have robust and long-lasting immunity.
While most side effects in children have been short-lived, at least seven deaths among 12- to 17-year-olds had been reported as of June 11, 2021, as well as 271 events rated “serious.”2 In the long term, there’s really no telling what might happen, and that’s a really important point.
As noted by Doshi, during the 2009 swine flu pandemic, narcolepsy didn’t become apparent until nine months after vaccination with the Pandemrix vaccine, and it wasn’t until four months into Israel’s COVID-19 vaccination campaign that heart damage was recognized as a side effect in young men and boys.
Cocooning Does Not Work
Doshi goes on to explain why vaccinating children will not likely benefit adults, as claimed. This practice, sometimes referred to as “cocooning,” has never actually been proven. Doshi cites a 2021 BMJ editorial3 in which the authors stressed that vaccinating children against COVID-19 is “hard to justify right now,” seeing how children experience only mild disease and transmission by children is limited, while the possibility of unintended consequences is high.
“Should childhood infection (and re-exposures in adults) continue to be typically mild, childhood vaccination will not be necessary to halt the pandemic,” the authors state.4
“The marginal benefits should therefore be considered in the context of local healthcare resources, equitable distribution of vaccines globally, and a more nuanced understanding of the differences between vaccine and infection induced immunity.
Once most adults are vaccinated, circulation of SARS-CoV-2 may in fact be desirable, as it is likely to lead to primary infection early in life when disease is mild, followed by booster re-exposures throughout adulthood as transmission blocking immunity wanes but disease blocking immunity remains high. This would keep reinfections mild and immunity up to date.”
Doshi points out that even if you believe that a small benefit is better than nothing, you must remember that this is an unproven hypothetical benefit. We would need a proper randomized controlled trial to ascertain whether vaccinating children might actually benefit adults. “We need confirmatory evidence, not just assumptions,” Doshi says.